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Abbreviations 
 
Ala: L-Alanine                            Asn: L-Asparagine 
Arg: L-Arginine                           Asp: L-Aspartic acid 
Cys: L-Cysteine                           Glu: L-Glutamic acid 
Gly: L-Glycine                            His: L-Histidine 
Ile: L-Isoleucine                           Leu: L-Leucine 
Lys: L-Lysine                             Met: L-Methionine 
Phe: L-Phenylalanine                       Pro: L-Proline 
Ser: L-Serine                              Thr: Threonine 
Trp: L-Tryptophan                         Tyr: L-Tyrosine 
Val: L-Valine 
 
β-HA: β-hexosaminidase                    C5a: complement component 5a 
EC: effective concentration            ELISA: enzyme-linked immunosorbent assay 
EMCS: N-(6-maleimidocapryloxy)succinimide       ER: endoplasmic reticulum  
fMLF: formyl-Met-Leu-Phe                  FPR2: formyl peptide receptor-2 
HBHS: HEPES-buffered Hank's solution      hMCT-2: human homologue of MCT-2 
IL-8: interleukin 8                         Kd: dissociation constant 
KLH: keyhole-limpet hemocyanin             mAb: monoclonal antibody               
MCT-CYC: mitocryptide-CYC                 MCTs: mitocryptides 
MCT-1: mitocryptide-1                       MCT-2: mitocryptide-2 
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mtDNA: mitochondrial DNA 
mtDAMPs: mitochondrial damage-associated molecular patterns 
ND-6: NADH dehydrogenase subunit 6 (1-6)      PBS: phosphate-buffer saline 
PBS-T: PBS containing 0.05% Tween 20     pMCT-1: porcine homologue of MCT-1 
pMCT-2: porcine homologue of MCT-2 
RP-HPLC: reverse-phase high-performance liquid chromatography. 
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Chapter I 
General Introduction 
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 Endogenous bioactive peptides involve in various physiological regulations. 
They play physiological roles like endocrine factors such as insulin and glucagon, and 
paracrine factors such as somatostatin, or neurotransmitters including substance P, 
neurokinins, and opioid peptides. These bioactive peptides are physiologically produced 
and matured by specific cleavages from their inactive precursor proteins by processing 
enzymes in endoplasmic reticulum (ER) and trans-Golgi network, and are stored in 
secretory vesicles [1]. They are then released by the various physiological stimulation to 
regulate a variety of biological functions including neurotransmission, blood pressure, 
and endocrinological responses. 
 It is of keen interest in bioactive peptides that produced by non-ER and 
non-trans-Golgi network recently. Namely, functional proteins are firstly synthesized as 
precursor proteins on ribosomes according to mRNA transcribed from DNA. The 
precursor proteins are cleaved by various processing enzymes and are folded into their 
appropriate conformation by the assistance of molecular chaperones to exhibit their 
functions. After playing their physiological roles, they are inactivated by various 
proteases and lose their bioactivities as well as their native conformation. During these 
maturation and degradation process, many kinds of fragmented peptides are 
simultaneously produced, but physiological significance of such abundant fragmented 
peptides has not been of much interest for a long time [2]. 
  Recently, it was demonstrated that some of fragmented peptides efficiently 
initiate innate immune responses including neutrophil activation. Namely, novel 
neutrophil-activating peptides, mitocryptide-1 (MCT-1), mitocryptide-2 (MCT-2), and 
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mitocryptide-CYC (MCT-CYC) have been isolated and identified from healthy porcine 
hearts (Figure I) [3–8]. MCT-1, MCT-2 and MCT-CYC were found to be endogenously 
fragmented peptides derived from mitochondrial cytochrome c oxidase subunit VIII, 
cytochrome b and cytochrome c, respectively. In addition, more than 50 different 
mitochondrial protein-derived peptides that efficiently activate neutrophilic cells have 
been identified utilizing bioinformatic approaches [2]. These findings propose that 
mitocryptides (MCTs), a novel family of neutrophil-activating peptides derived from 
various mitochondrial proteins, regulate innate immune responses. Such cryptic 
peptides with distinct bioactivities from their parent proteins have been designated as 
"cryptides" in general [2]. Signaling mechanisms of MCTs have been also intensively 
investigated in cellular levels, and it was indicated that these MCTs induce neutrophilic 
phagocytosis and migration via the activation of Gi-type G proteins and ERK1/2 
phosphorylation [5–7]. Regarding receptor molecules for MCTs, formyl peptide 
receptor 2 (FPR2, also termed as formyl peptide receptor like 1) is a specific receptor 
for MCT-2 [7], although receptors for MCTs other than MCT-2 have not been identified 
yet.  
 After the discovery of MCTs, many fragmented peptides derived from various 
functional proteins including hemoglobin and proteinase-activated receptor 1, both of 
which efficiently induce a variety of biological functions, have been identified [9–15], 
and it is of particular interest to investigate their physiological significance. However, 
investigation of physiological production and distribution of those cryptides was very 
difficult, because immunostainning with antibodies that bind to their peptide sequences 
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can not distinguish between cryptides and their parent proteins. Furthermore, it is hard 
to elucidate physiological roles of those cryptides. In general, physiological 
involvements of endogenous bioactive peptides and functional proteins are clarified by 
manipulation of their genes. Since cryptides constitute a part of their parent proteins, 
gene manipulation of them inevitably influences the functions and expression levels of 
their parent proteins. To overcome these difficulties on elucidation of physiological 
significance of cryptides, alternative strategies are thus required to establish. If we have 
monoclonal antibodies (mAbs) that recognize cryptides but not their parent proteins, it 
would be able to analyze the production and localization of cryptides themselves. 
Specific neutralizing mAbs against MCTs are expected to make us investigate exactly 
their physiological roles in vivo.  
 In the present study, since MCT-1 is proposed to be a most abundant 
mitocryptide [5], I prepared specific neutralizing mAb against MCT-1. The neutralizing 
mAb enables us to investigate its physiological roles without the influence to the 
functions of its parent protein, cytochrome c oxidase subunit VIII (Chapter II). I also 
tried to aquire mAbs against MCT-2 because MCT-2 is an endogenous N-formyl 
peptide that is proposed to involve in innate immunity [6, 7]. Here, I obtained an mAb 
that recognized a cleavage site of MCT-2 from cytochrome b. This characteristic 
enables us to analyze the production and localization of MCT-2 because the mAb 
specifically binds to MCT-2 but not to its parent protein, cytochrome b. I also 
successfully prepared a neutralizing mAb that specifically prevents bioactivities of 
MCT-2. (Chapter III). 
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Figure I. Primary structures of MCT-1, MCT-2 and MCT-CYC derived from their 
parent proteins.  
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II-1. Abstract 
 Mitocryptide-1 (MCT-1) is a novel neutrophil-activating peptide derived from 
mitochondrial cytochrome c oxidase subunit VIII, and its physiological role and 
involvement in various diseases have not yet been elucidated. Generating neutralizing 
antibodies against the function of MCT-1 is of particular importance for investigating 
its physiological and pathophysiological roles, because MCT-1 is a fragmented peptide 
of its parent protein and hence it is very difficult to manipulate its expression level 
genetically without affecting expression of the parent protein. Here, I describe the 
successful generation of a neutralizing monoclonal antibody (mAb) against MCT-1. 
This mAb, designated NM1B1, which specifically bound to the region of positions 9–22 
of MCT-1, showed concentration-dependent inhibition of MCT-1-induced migration 
and β-hexosaminidase release in neutrophilic/granulocytic differentiated HL-60 cells. 
Thus, NM1B1, as a neutralizing mAb against MCT-1, could elucidate not just the 
physiological regulatory mechanisms of MCT-1 but also its pathophysiological 
involvement in various inflammatory diseases in vivo. 
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II-2. Introduction 
 Mitochondrial contents had been paid attention as pro-inflammatory factors, 
i.e. it was shown that the contents of disrupted mitochondria, which are presumably 
released from necrotic cells in damaged tissues, promoted neutrophilic migration [16]. 
However, endogenous neutrophil-activating factors had not yet been identified for a 
long time. To discover such neutrophil-activating substances, MCT-1 was purified and 
identified as endogenous neutrophil-activating peptide from healthy porcine heart [5]. 
MCT-1 is a tricosapeptide derived from C-terminus of mitochondrial cytochrome c 
oxidase subunit VIII (Figure I) and efficiently promotes phagocytosis and migration of 
neutrophils at nano-molar concentrations. However, the involvement of MCT-1 in 
innate immunity associating with neutrophil responses has not yet been investigated. 
Since MCT-1 is a peptide fragment that presumably produced by enzymatic cleavage of 
its parent protein, cytochrome c oxidase subunit VIII, silencing of this gene inevitably 
affects the functions and expression levels of its parent protein. In this study, I thus 
acquired neutralizing mAb that specifically inhibited bioactivities of MCT-1 to 
alternatively elucidate physiological and pathophysiological significance of MCT-1.  
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II-3. Materials and Methods 
II-3-1. Peptides synthesis 
 MCT-1 and its derivatives were synthesized by a solid-phase method using a 
9-fluorenylmethyloxycarbonyl strategy [17–20]. Synthesized peptides were purified by 
reverse-phase high-performance liquid chromatography (RP-HPLC) on a 5C18 column 
(20 × 250 mm; COSMOSIL, Nacalai Tesque, Inc., Kyoto, Japan). These peptides were 
then analyzed by RP-HPLC on a 5C18 column (4.6 × 150 mm; COSMOSIL, Nacalai 
Tesque, Inc.) and were demonstrated to be more than 95% pure. Molecular weights of 
the synthesized peptides were confirmed by matrix-assisted laser desorption ionization 
time-of-flight mass spectrometry. 
 
II-3-2. Preparation of a peptide antigen 
 To prepare a peptide antigen, [Cys0]MCT-1 was conjugated with bovine 
thyroglobulin as a carrier protein via N-(6-maleimidocaproyloxy)succinimide (EMCS; 
Dojindo Molecular Technologies, Kumamoto, Japan). Namely, the ε-amino groups of 
Lys residues of thyroglobulin were coupled with the N-hydroxysuccinimide group of 
EMCS in phosphate-buffered saline (PBS; pH 7.0) at 37°C for 1 h to produce 
thyroglobulin-EMCS complexes. Then, the reacted solution was diluted with PBS and 
ultrafiltrated to remove unreacted EMCS. Thereafter, the maleimide groups of 
thyroglobulin-EMCS were reacted with the sulfhydryl group of [Cys0]MCT-1 in PBS 
(pH 7.0) for 3 h at room temperature to obtain MCT-1-EMCS-thyroglobulin complexes. 
The quantity of MCT-1 bound to thyroglobulin was estimated using an AmpliteTM 
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Fluorimetric Maleimide Quantitation Kit (AAT Bioquest, CA, USA). The resultant 
MCT-1-EMCS-thyroglobulin complexes were used as an antigenic peptide and stored at 
-80°C before use. 
 
II-3-3. Production of mAbs 
 The animal experiments in the present study were approved by the Animal 
Care and Use Committee of the Nagahama Institute of Bio-Science and Technology. 
Eight-week-old female BALB/c mice were injected subcutaneously with the peptide 
antigen (per head, 7 mg MCT-1 conjugated with thyroglobulin dissolved in 300 µL 
PBS) mixed with 300 µL Freund’s complete adjuvant (Rockland, PA, USA). The mice 
were boosted with the same amount of peptide antigen in PBS mixed with Freund’s 
incomplete adjuvant (Rockland) at 7, 14, and 21 days after the first immunization. 
Three days prior to sacrifice, the mice were boosted intraperitoneally once with the 
same amount of the peptide antigen in PBS without any adjuvant. 
 mAbs were generated by the standard method with slight modifications [21, 
22]. Spleen cells obtained from immunized mice were fused with myeloma cells (PAI 
cells; Human Science Research Resources Bank, Tokyo, Japan) at a ratio of 10:1 using 
Dulbecco-PBS with 45% (w/v) polyethylene glycol 4000 (Immuno-Biological 
Laboratories, Gunma, Japan). Hybridoma cells were selected in GIT medium (Kohjin 
Bio, Saitama, Japan) containing 100 µM hypoxanthine, 0.4 µM aminopterin, and 16 µM 
thymidine (Sigma-Aldrich, MI, USA) for 10 days in a 96-well microtiter plate (Corning, 
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NY, USA). Hybridoma cells producing anti-MCT-1 antibodies were screened and 
cloned by enzyme-linked immunosorbent assay (ELISA). ELISA plates (Thermo Fisher 
Scientific, MA, USA) were coated with 50 ng/well MCT-1 conjugated with 
keyhole-limpet hemocyanin (KLH) via EMCS (MCT-1-EMCS-KLH) in 0.1 M 
carbonate buffer for 16 h at 4°C and blocked with 200 µL protein solution (5 × dilution 
of saturated casein solution in PBS, pH 7.2; Nacalai Tesque, Inc.) at 37°C for 2 h. The 
culture supernatants (50 µL) were then added to each well of the ELISA plate and 
incubated for 30 min at 37°C. After washing with PBS containing 0.05% Tween 20 
(PBS-T) 5 times, 50 µL goat anti-mouse IgG conjugated with horseradish peroxidase 
(0.5 µg/mL; Life Technologies, CA, USA) were added. Then, the plates were incubated 
for 30 min at 37°C, followed by washing with PBS-T 6 times. ABTS peroxidase 
substrate solution (Kirkegaard & Perry Laboratories, MD, USA) was added to each well 
and incubated at room temperature for 10 min in the dark to develop color. The reaction 
was stopped by addition of 100 µL of 1% sodium dodecyl sulfate, and absorbance was 
measured at 405 nm using a microplate reader (Viento XS; Bio-Tek Instruments, VT, 
USA). Isotypes of mAbs were confirmed by IsoStrip (Mouse Monoclonal Antibody 
Isotyping Kit; Roche, Basel, Switzerland) according to the manufacturer’s instructions. 
 Each cloned hybridoma cell producing an anti-MCT-1 mAb (2.5 × 107 cells) 
was cultured in a flask (CELLine Flask; Corning) with GIT medium for 1 week to 
obtain the mAb from the culture supernatant according to the manufacture's instruction. 
The culture supernatant was then collected and cell debris in the supernatant was 
removed by centrifugation at 400 × g for 10 min. mAbs in the supernatant were purified 
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by protein G affinity chromatography (Protein G Sepharose 4 Fast Flow; GE Healthcare, 
Little Chalfont, UK). The purified mAbs were collected and dialyzed with PBS at pH 
7.4. The mAbs were dispensed into microtubes and stored at -30°C. 
 
II-3-4. Characterization of the mAbs 
 The binding specificity and dissociation constant (Kd) of the anti-MCT-1 
mAbs were evaluated by competition ELISA [23]. Briefly, the anti-MCT-1 mAb 
solution was mixed with various concentrations of MCT-1, human mitocryptide-2 
(hMCT-2) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF), and incubated 
at 37°C for 2 h. The incubated solutions (50 µl) were then added to each well of the 
ELISA plate containing immobilized MCT-1-EMCS-KLH (150 ng/well) and incubated 
at 37°C for 30 min. The anti-MCT-1 mAbs that bound to the well were evaluated 
subsequently by ELISA as described above. The Kd value was calculated by Scatchard 
plot analysis. 
 The antigen binding properties of anti-MCT-1 mAbs were also analyzed by 
competition ELISA using MCT-1 derivatives. Two hundreds nano-molar of the 
anti-MCT-1 mAbs (60 µL) were mixed with 60 µM of various MCT-1 derivatives (60 
µL) and they were incubated at 37°C for 2 h. The solutions were then added to each 
well of the ELISA plate with immobilized MCT-1-EMCS-KLH and further incubated 
for 30 min at 37°C. The anti-MCT-1 mAbs that bound to the well were evaluated by 
ELISA as described above. 
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II-3-5. Evaluation of neutralizing activity 
 HL-60 cells (RIKEN Cell Bank, Ibaraki, Japan) were cultured in RPMI-1640 
medium (Life Technologies) containing 10% fetal bovine serum (Life Technologies) in 
a humidified atmosphere of 5% CO2 at 37°C. HL-60 cells (3.2 × 107 cells / 40 mL) in a 
75-cm2 flask (Asahi Glass, Chiba, Japan) were treated with 500 µM dibutyryl cyclic 
adenosine monophosphate (Sigma-Aldrich) for 72 h for differentiation into 
neutrophilic/granulocytic cells [24]. 
 β-Hexosaminidase (β-HA) release from the differentiated HL-60 cells was 
analyzed as described previously [5, 6] with slight modifications. In brief, differentiated 
HL-60 cells were washed 3 times with ice-cold HEPES-buffered Hank’s solution 
(HBHS; 10 mM HEPES, 136.9 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 0.44 mM 
KH2PO4, 0.49 mM MgCl2, 0.41 mM MgSO4, 0.34 mM Na2HPO4, 5.5 mM glucose, and 
4.2 mM NaHCO3 at pH 7.4) containing 0.1% bovine serum albumin and resuspended in 
HBHS at a density of 1.0 × 107 cells/mL. Then, 50 µL of the cell suspension were 
transferred to a tube (5.0 × 105 cells/tube) and placed on ice; DNase I (Sigma-Aldrich) 
and cytochalasin B (Sigma-Aldrich) were both added to the cell suspension at a final 
concentration of 5 µg/mL. After pre-incubation of the cell suspension for 10 min at 
37°C, the cells were stimulated for 10 min at 37°C with 1 µM MCT-1, 0.7 µM hMCT-2, 
or 3 nM fMLF solution (50 µL) pre-incubated with or without various concentrations of 
the anti-MCT-1 mAbs. The cells were also stimulated with MCT-1 (1 µM) 
pre-incubated with 1 µM of the isotype/subclass matched control mAb (LEAFTM 
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purified mouse IgG1, κ isotype control; BioLegend, CA, USA). Thereafter, 200 µL 
ice-cold reaction-quenching buffer (25 mM Tris, 123 mM NaCl, and 2.7 mM KCl at pH 
7.4) were added to each cell suspension to stop stimulation. The tubes were centrifuged 
at 4°C and 2300 × g for 1 min, and each cell supernatant was transferred to a new tube.  
 β-HA activity in the cell-free supernatant was determined as described 
previously with minor modifications [25]. Briefly, 90 µL of the supernatant obtained as 
described above were transferred to each well of a 96-well microtiter plate, and 60 µL 
of a substrate solution for β-HA (10 mM 4-nitrophenyl N-acetyl-β-D-glucosaminide 
[Sigma-Aldrich], 40 mM citrate, and 70 mM NaHPO4 at pH 4.5) were added to initiate 
the enzyme reaction. After incubation of the plate at 37°C for 70 min, 100 µL 
reaction-quenching solution (400 mM glycine at pH 10.7) were added to stop the 
enzyme reaction. Thereafter, the absorbance difference of each well at 415 nm for the 
resulting 4-nitrophenol and at 490 nm for the reference absorbance was measured. 
β-HA activity in each supernatant was estimated as a percentage of total enzyme 
activity, which was enzyme activity released after lysis of the cells with 0.05% Triton 
X-100. β-HA releasing activity stimulated by 60% of effective concentration (EC60) of 
each peptide with various concentrations of the anti-MCT-1 mAbs or the 
isotype/subclass matched control mAb was expressed as a percentage of that without 
the anti-MCT-1 mAbs. 
 Chemotaxis of differentiated HL-60 cells was assessed as described 
previously [5,  6] with slight modifications. In brief, differentiated HL-60 cells were 
washed 3 times with HBHS at 37°C and resuspended in HBHS at a density of 4.0 × 106 
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cells/mL. After pre-incubation of the cell suspension at 37°C for 10 min, 500 µL of the 
cell suspension were transferred to a Chemotaxicell Chamber (2.0 × 106 cells/chamber; 
pore size, 3 µm; Kurabo, Osaka, Japan). The chambers were placed in a 24-well 
microplate filled with 1 mL preheated (37°C) HBHS containing 1 µM MCT-1, which 
was pre-incubated with various concentrations of the anti-MCT-1 mAbs for 2 h. The 
microplate was incubated for 1 h at 37°C. The Chemotaxicell chambers were then 
removed from each well of the microplate, and the number of cells that had migrated 
into the lower side of the chambers was counted. Migration activity was estimated as a 
chemotaxis index; the number of cells that migrated with stimulation was divided by the 
number of cells that migrated without stimulation. Migration activity stimulated by 1 
µM MCT-1 with various concentrations of the anti-MCT-1 mAbs was expressed as a 
percentage of that without the anti-MCT-1 mAbs. 
 
II-3-6. Statistical analysis 
 Statistical comparisons were performed using Student’s t-test (two groups). 
The means and the standard errors of the means (SEM) were calculated in experiments 
containing multiple data points. Values of p < 0.05 were considered statistically 
significant. 
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II-4. Results 
II-4-1. Generation of anti-MCT-1 mAbs 
 The antibody titer against MCT-1 in the collected serum from the immunized 
mice increased at 1 month after the initial immunization with 
MCT-1-EMCS-thyroglobulin. Eleven hybridoma clones producing mAbs that showed a 
positive reaction against MCT-1 in ELISA were obtained by screening and cloning 
fused cells of splenic cells from the immunized mice and myeloma cells. One clone, 
MCT-1-B-1, produced a considerable amount of an mAb with higher affinity to MCT-1 
than the other clones. The isotype of the purified mAb from the culture supernatant of 
the MCT-1-B-1 clone was identified as IgG1. This purified mAb, designated as NM1B1, 
exhibited positive reactivity to the ELISA plate with immobilized MCT-1-EMCS-KLH. 
 
II-4-2. Binding specificity 
 Since NM1B1 was shown to bind to MCT-1-EMCS-KLH, competition 
ELISA was performed to confirm whether it bound to MCT-1 itself. Binding of NM1B1 
(30 nM) to each well of an ELISA plate with immobilized MCT-1-EMCS-KLH was 
reduced by free MCT-1 at concentrations above 3 µM, and was almost completely 
inhibited by 10 µM free MCT-1 (Fig. II-1-A). These results demonstrate that MCT-1, 
but not linker nor KLH, actually binds to NM1B1. Competition of other 
neutrophil-activating peptides to the binding of NM1B1 with immobilized 
MCT-1-EMCS-KLH was also investigated. NM1B1 (30 nM) without any competitors 
bound to the well, whereas isotype/subclass-matched control mAb did not (Fig. II-1-B). 
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Free MCT-1 at a concentration of 10 µM almost completely inhibited the binding of 
NM1B1 to the well. On the contrary, binding of NM1B1 to the well was not prevented 
by 10 µM free hMCT-2 or fMLF. These results indicate that NM1B1 specifically 
recognized MCT-1. Scatchard analysis of competitive ELISA revealed that the Kd value 
of antibody-peptide binding were 571 ± 54 nM. 
 
II-4-3. Epitope characterization 
 As NM1B1 was shown to bind specifically to MCT-1, an epitope of NM1B1 
was examined by competitive ELISA using an MCT-1-EMCS-KLH immobilized plate 
(Fig. II-2). I prepared 3 fragment peptides of MCT-1: MCT-1 (1–11), MCT-1 (7–17), 
and MCT-1 (13–23) (Fig. II-2-A). These peptides are 11 amino acid residues in length 
and overlap by 5 residues. These 3 fragment peptides spanning the entire sequence of 
MCT-1 were used as competitors. MCT-1 (7–17) (30 µM) inhibited binding of NM1B1 
to the well, whereas MCT-1 (1–11) and MCT-1 (13–23) did not, showing the region at 
positions 7–17 of MCT-1 has a part of the epitope. 
 To elucidate the binding site of NM1B1 more accurately, the competitive 
effects of MCT-1 (8–17) and MCT-1 (9–17), which were derivatives of MCT-1 (7–17) 
truncated at the N-terminal by 1 and 2 amino acids, respectively, were further examined 
(Fig. II-2-A). These two derivatives inhibited the binding of NM1B1 to the well by 
approximately 20%, which was almost the same extent as MCT-1 (7–17). Conversely, 
MCT-1 (10–17), which was a derivative truncated by 3 amino acids, did not inhibit 
binding at all (Fig. II-2-B). These results demonstrate that Trp9 of MCT-1 is crucial for 
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the binding of NM1B1 to the well. 
 Nonetheless, the inhibitory effects of MCT-1 (7–17), MCT-1 (8–17), and 
MCT-1 (9–17) (30 µM) were much less than that of MCT-1 itself. I also investigated 
the competing effects of C-terminal extended derivatives of MCT-1 (9–17) on binding 
to the well. As a result, 30 µM MCT-1 (9–18) and MCT-1 (9–19) inhibited binding to 
the plate by approximately 50% and 80%, respectively (Fig. II-2-B). These results 
indicate that Lys18 and Arg19 of MCT-1 are essential for NM1B1 binding. The fragments 
MCT-1 (9–22) and MCT-1 (9-23) inhibited the binding to the well to the similar level 
as MCT-1 itself (Fig. II-2-B). These results strongly demonstrate that the positions 9–22 
region of MCT-1 is sufficient for the binding of NM1B1 to MCT-1, and at least Trp9, 
Lys18, and Arg19 of MCT-1 are essential amino acids for the epitope of NM1B1. 
 
II-4-4. Inhibitory effects of the anti-MCT-1 mAb on MCT-1-induced bioactivity 
 Since NM1B1 was shown to bind specifically to MCT-1, I investigated 
whether the mAb inhibited MCT-1-induced bioactivity in neutrophilic cells. The 
inhibitory activity of the mAb on β-HA release induced by various neutrophil-activating 
peptides in neutrophilic/granulocytic differentiated HL-60 cells was compared at 
concentrations that gave approximately 60% of the maximum effects of the peptides. As 
shown in Fig. II-3, β-HA release induced by MCT-1 (1 µM) was reduced in a 
dose-dependent manner by pre-incubation of MCT-1 with NM1B1 at concentrations 
above 0.3 µM and was inhibited completely at 1 µM, whereas the control mAb did not 
block its release. NM1B1 neither altered the enzyme release caused by hMCT-2 (0.7 
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µM) nor fMLF (3 nM), even at a concentration as high as 1 µM. These results indicate 
that NM1B1 specifically inhibits β-HA release induced by MCT-1. 
 The inhibitory effect of NM1B1 on MCT-1-induced chemotaxis of 
differentiated HL-60 cells was also investigated. NM1B1 at concentrations above 0.3 
µM significantly prevented cell migration (Fig. II-4). These results demonstrate that 
NM1B1 is able to act as a specific anti-chemotaxis factor. 
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II-5. Discussion 
 Neutrophils are involved in innate immunity by monitoring infections and 
tissue damage and by scavenging toxic debris at inflammatory sites [26, 27]. 
Neutrophils immediately infiltrate damaged sites from the bloodstream to remove toxic 
substances. Some CXC chemokines including interleukin 8 (IL-8), complement-related 
factors such as complement component 5a (C5a), and lipid mediators such as lipoxin A4 
are known endogenous chemoattractants for neutrophils [28–30]. It has also been shown 
that bacterial N-formylated peptides and proteins induce neutrophil migration [31–33], 
but the mechanisms of acute inflammation involving neutrophils remain unclear. 
However, much evidence suggests that mitochondria-derived factors are involved in 
sterile immune responses. Namely, it has been demonstrated that the contents of 
disrupted mitochondria that are probably released from necrotic cells promote 
neutrophil migration [16]. Recently, a family of neutrophil-activating cryptides, 
mitocryptides, including MCT-1, MCT-2, and mitocryptide-CYC were isolated and 
identified [2–8]. Among these mitocryptides, MCT-1 was purified and identified 
initially from porcine heart [5]. However, the physiological and pathophysiological 
roles of MCT-1 in vivo are still uncertain. In order to elucidate these functions of 
MCT-1 in vivo, it is valuable to investigate them by utilizing inhibition of physiological 
and pathophysiological phenotypes with specific neutralizing antibodies, because it is 
difficult to manipulate the expression level of MCT-1 genetically without affecting that 
of its parent protein, cytochrome c oxidase subunit VIII. 
 In the present study, I successfully obtained NM1B1 mAb that bound 
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specifically to MCT-1 and inhibited migration and β-HA release induced by MCT-1 in 
neutrophilic/granulocytic cells. These results demonstrate that NM1B1 is a specific 
neutralizing mAb against the biological functions of MCT-1. In addition, NM1B1 
recognized amino acids at positions 9–22 of MCT-1, including the side chains of Trp9, 
Lys18, and Arg19, suggesting that NM1B1 may recognize the conformational structure of 
the MCT-1 (9–22) region. 
 Interestingly, accumulating evidence shows that mitochondrial-derived 
contents regulate acute inflammation involving neutrophils. Mitochondrial 
damage-associated molecular patterns (mtDAMPs) that contain mitochondrial DNA and 
mitochondrial-derived proteinaceous molecules are released from mitochondria in the 
injured tissues of traumatic patients and cause systemic inflammation by promoting 
neutrophil activation [34, 35]. Although proteinaceous molecules in mitochondrial 
DAMPs have not been identified, they may contain mitochondrial-derived 
peptides—mitocryptides, including MCT-1—because MCT-1 is considered to be the 
most abundant neutrophil-activating mitochondrial-derived peptide in healthy organs. 
Specific neutralizing mAbs against mitocryptides including NM1B1, which was 
obtained in the present study, are expected to be useful for the identification of the 
proteinaceous factors in mitochondrial DAMPs and elucidation of acute inflammation 
mechanisms involving mitocryptides and neutrophils. Moreover, I expect these mAbs to 
contribute to open a window for the functional investigation of the biological roles of 
cryptides that are hidden in functional protein sequences. 
In conclusion, I successfully obtained NM1B1 that binds specifically to MCT-1 and 
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neutralizes its biological functions in neutrophilic/granulocytic cells. This neutralizing 
mAb is expected to be a useful tool for investigating the physiological and 
pathophysiological functions of MCT-1 in vivo.  
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Fig. II-1. Binding properties of NM1B1 to MCT-1.  
(A) Binding activity of NM1B1 (30 nM) to the well was examined in the presence of 
various concentrations of free MCT-1 as a competitor. (B) Binding specificity of 
NM1B1 (30 nM) was investigated by competition with MCT-1, hMCT-2, and fMLF 
(10 µM) to mAb binding to the well. A control mAb with the matched isotype/subclass 
to NM1B1 (30 nM) without competitive peptides was also tested as a negative control. 
***p < 0.001 compared with vehicle. Data are expressed as the mean ± SEM of 3 
independent experiments.  
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Fig. II-2. Mapping the NM1B1 epitope.  
(A) Sequences of MCT-1 and its derivatives used for epitope mapping. (B) Inhibitory 
activity of MCT-1 and its derivatives (30 µM) for mAb binding to the well. Data are 
expressed as the mean ± SEM of 3 independent experiments. 
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Fig. II-3. Inhibitory activity of NM1B1 on the stimulation of β-HA release by 
MCT-1, hMCT-2, and fMLF.  
β-HA release from neutrophilic/granulocytic differentiated HL-60 cells stimulated by 
the EC60 of each peptide without NM1B1 was defined as the positive control. Enzyme 
release in the presence of various concentrations of NM1B1 or the isotype/subclass 
matched control mAb was expressed as a percentage of the positive control. Each value 
is the mean ± SEM of the duplicate determination of 6 (MCT-1 stimulation with 
NM1B1) or 3 (hMCT-2 or fMLF stimulation with NM1B1 and MCT-1 stimulation with 
control mAb) separate experiments. **p < 0.01, ***p < 0.001 compared with each 
peptide stimulation without NM1B1. 
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Fig. II-4. Inhibitory effects of NM1B1 on chemotaxis induced by MCT-1. 
Neutrophilic/granulocytic differentiated HL-60 cells were stimulated using 1 µM 
MCT-1 with various concentrations of NM1B1or without it. Inhibition of chemotaxis 
by NM1B1 was expressed as relative to the activity in the absence of the mAb. Data are 
expressed as the mean ± SEM of 3 independent experiments. **p < 0.01, ***p < 0.001 
compared with the chemotaxis index in the absence of the mAb. 
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Chapter III 
Generation of monoclonal antibodies against 
mitocryptide-2: Toward a new strategy to 
investigate the biological roles of cryptides 
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III-1. Abstract 
 Recently a novel family of neutrophil-activating peptides including 
mitocryptide-1 and mitocryptide-2 (MCT-2) that endogenously produced from various 
mitochondrial proteins are identified. Among them, MCT-2 is an N-formylated 
pentadecapeptide derived from mitochondrial cytochrome b and is found to promote 
neutrophilic migration and phagocytosis efficiently. Signaling mechanisms of 
neutrophil activation by MCT-2 have been investigated at the cellular level, and MCT-2 
has been demonstrated to be an endogenous specific ligand for formyl peptide 
receptor-2 (FPR2, also referred to as formyl peptide receptor-like 1). It was also found 
that MCT-2 promoted neutrophilic functions via the activation of Gi2 proteins and 
phosphorylation of ERK1/2 consecutively. However, the physiological production, 
distribution, and functions of MCT-2 are not yet elucidated. Here, to investigate the 
roles of MCT-2 in vivo, I generated monoclonal antibodies (mAbs) against human 
MCT-2 (hMCT-2) that have two different characteristics. One mAb, NhM2A1, not only 
bound to the region of positions 10–15 of hMCT-2 but also recognized its C-terminal 
cleavage site that is presumably produced upon enzymatic hydrolysis of cytochrome b, 
indicating that NhM2A1 specifically interacts with hMCT-2 but not its parent protein. 
Moreover, I succeeded in acquiring a specific neutralizing mAb, NhM2A5, which 
blocks the bioactivities of hMCT-2. Specifically, NhM2A5 inhibited hMCT-2-induced 
β-hexosaminidase release in neutrophilic/granulocytic differentiated HL-60 cells by 
binding to the region of positions 5–12 of hMCT-2. Functional analysis using obtained 
mAbs that specifically recognize hMCT-2 but not its parent protein, cytochrome b, and 
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that neutralize bioactivities of hMCT-2 is expected to reveal the physiological roles of 
MCT-2, which are presently very difficult to investigate. 
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III-2. Introduction 
 Recently, mitochondrial damage-associated molecular patterns (mtDAMPs) 
are paid much attention as pro-inflammatory factors in sterile inflammation that were 
caused by internal tissue damages including ischemic injuries/infarction, burn and 
drug-induced liver injury [36-38]. mtDAMPs are considered to be released from the 
tissue injury sites, and are shown to induce neutrophil migration and activation. 
mtDAMPs are also proposed to be comprised of various inflammatory factors including 
mitochondrial DNA (mtDNA) and formyl peptides [34]. However, highly purified 
mtDNA was recently demonstrated to be unable to activate neutrophils in vitro [39, 40]. 
Moreover, endogenous formyl peptides in mtDAMPs have not yet been molecularly 
specified yet.  
 MCT-2 was an endogenous neutrophil-activating formylated 
pentadecapeptide that was isolated and identified from healthy porcine hearts [6]. It was 
found to be a fragmented peptide derived from N-terminus of cytochrome b encoded in 
mtDNA (Figure I) [6]. Signaling mechanisms of MCT-2 in cellular level have been 
intensively investigated. MCT-2 efficiently induced neutrophilic phagocytosis and 
migration at nano-molar concentrations via activation of Gi type G proteins associating 
with ERK1/2 phosphorylation [6, 7], and is also demonstrated to be a specific 
endogenous agonist for FPR2. Base on these findings, we propose that MCT-2 is one of 
activating factors in mtDAMPs. However, not only physiological production and 
distribution of MCT-2 but also its pathogenic involvement in sterile inflammation 
associating with excessive neutrophilic responses have not yet been elucidated. Here, to 
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establish the new strategies for investigation of physiological roles of MCT-2, I 
acquired mAbs with two different features. One was mAb that recognized a cleavage 
site in the human homolog of MCT-2 (hMCT-2, Table III-1) that is created during 
enzymatic hydrolysis of cytochrome b. This characteristic enables me to analyze the 
production and localization of hMCT-2 because the mAb specifically binds to hMCT-2 
but not to its parent protein, cytochrome b. Another was mAb that specifically 
prevented bioactivities of hMCT-2. Fortunately, this neutralizing mAb allows me to 
investigate its physiological roles without influencing the functions of its parent protein. 
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III-3. Materials and Methods 
III-3-1. Peptide synthesis 
 MCT-2 (porcine) and its human and mouse homologs as well as their 
derivative peptides were synthesized by a solid-phase method using a 
9-fluorenylmethyloxycarbonyl strategy as described in Chapter II [17–20]. Purified 
peptides were proven to be more than 95% pure by analytical high-performance liquid 
chromatography using a COSMOSIL 5C18-AR-II column (4.6 × 150 mm; Nacalai 
Tesque, Inc., Kyoto, Japan). Homogeneity of the synthesized peptides was confirmed 
using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. 
 
III-3-2. Preparation of peptide antigen 
 The hMCT-2 antigen was prepared by conjugation with an hMCT-2 
derivative, which was modified by the addition of a Cys residue at the N-terminus 
([Cys0]hMCT-2), and thyroglobulin as carrier protein via 
N-(6-maleimidocaproyloxy)succinimide (EMCS, Dojindo Molecular Technologies, 
Kumamoto, Japan), as described previously [41]. Briefly, bovine thyroglobulin 
(Sigma-Aldrich, MO, USA) was reacted with EMCS in phosphate-buffered saline (PBS, 
pH 7.0) at 37°C for 1 h to prepare thyroglobulin-EMCS complexes. The sulfhydryl 
group of [Cys0]hMCT-2 was then coupled with the maleimide group of 
thyroglobulin-EMCS in PBS (pH 7.0) at room temperature for 3 h. The obtained 
peptide antigen, hMCT-2-EMCS-thyroglobulin, was store at –80°C until use. 
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III-3-3. Development of mAbs 
 The animal experiments were conducted under the guidance of Animal Care 
and Use Committee of the Nagahama Institute of Bio-Science and Technology 
(Approval No. 047). An emulsion of the peptide antigen was prepared by mixing with 
the peptide antigen described above and Freund's complete adjuvant (Rockland, PA, 
USA). Eight-week-old female BALB/c mice (Oriental Bio Service, Kyoto, Japan) were 
subcutaneously injected with the emulsion. After the first immunization, these mice 
were boosted with an emulsion composed of an identical amount of the peptide antigen 
and Freund's incomplete adjuvant (Rockland) once weekly for 1 month. For the final 
immunization, these mice were intraperitoneally injected with the peptide antigen 3 
days before sacrifice.  
 mAbs against hMCT-2 were generated according to standard methods with 
minor modifications [21, 22, 41]. Spleen cells from immunized mice and PAI cells 
(Human Science Research Resource Bank, Tokyo, Japan) were mixed at a ratio of 10:1. 
Then, cell fusion was performed with 45% (w/v) polyethylene glycol 4000 
(Immuno-Biological Laboratories, Gunma, Japan) in Dulbecco’s PBS. The produced 
hybridoma cells were selected in GIT medium (Kohjin Bio, Saitama, Japan) containing 
100 µM hypoxanthine, 0.4 µM aminopterin, and 16 µM thymidine (Sigma-Aldrich) for 
10 days at 37°C and 5% CO2 in a humidified atmosphere. Thereafter, hybridoma clones 
producing antibodies against hMCT-2 were screened by enzyme-linked immunosorbent 
assay (ELISA) using 96-well plates with immobilized hMCT-2 antigen as described 
below and cloned by limiting dilution. Isotypes of anti-hMCT-2 mAbs were examined 
 39 
by IsoStrip (Mouse Monoclonal Antibody Isotyping Kit, Roche, Basel, Switzerland) 
according to the manufacturer's instructions. 
 The cloned hybridoma cells producing anti-hMCT-2 mAbs were cultured in a 
CELLine Flask (Corning, NY, USA) using GIT medium for 1 week. The mAb in the 
cell culture supernatant was purified using Protein G Sepharose 4 Fast Flow (GE 
Healthcare, Little Chalfont, UK). The purified mAb was dialyzed in PBS (pH 7.4) and 
stored at –30°C before use. 
 
III-3-4. ELISA 
 Ninety-six-well microtiter plates were immobilized with hMCT-2 conjugated 
with keyhole-limpet hemocyanin (KLH) via EMCS (hMCT-2-EMCS-KLH) at a 
concentration of 50 ng/well in 0.1 M carbonate buffer (0.1 M Na2CO3 / NaHCO3, pH 
9.5) at 4°C for 18 h. Plates were then blocked with protein solution (200 µl of 5-fold 
dilution of saturated casein solution in PBS [Nacalai Tesque, Inc.]) for 2 h at 37°C, and 
washed with PBS containing 0.05% Tween 20 (PBS-T) 4 times. Anti-hMCT-2 mAb 
solution (50 µl of cell culture supernatant or purified mAb solution) was added, and the 
plates were incubated at 37°C for 30 min. After washing the plates 5 times with PBS-T, 
50 µl of goat anti-mouse IgG conjugated with horseradish peroxidase (0.5 µg/ml, Life 
Technologies, CA, USA) was added and the plates were incubated for 30 min at 37°C. 
The plates were again washed with PBS-T 6 times, and developed using 100 µl/well of 
ABTS peroxidase substrate solution (Kirkegaard & Perry Laboratories, Inc., MD, USA) 
at room temperature in the dark for 10 min. The enzyme reaction was stopped by 
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addition of 100 µl/well of 1% sodium dodecyl sulfate and absorbance at 405 nm was 
measured in a microtiter plate reader (Viento XS, BioTek Instruments, VT, USA). 
 
III-3-5. Binding specificity 
 Binding specificity of the anti-hMCT-2 mAbs was evaluated by competition 
ELISA. Anti-hMCT-2 mAbs were mixed with various competitor peptides. The mixture 
was incubated at 37°C for 2 h and then added to microtiter plates with immobilized 
hMCT-2-EMCS-KLH. Anti-hMCT-2 mAbs that bound to the plates were evaluated by 
ELISA as described above. The dissociation constant (Kd) of the anti-hMCT-2 mAbs 
was calculated by Scatchard analysis.  
 
III-3-6. Epitope mapping 
 Epitopes of hMCT-2 for the binding to mAbs were also examined by 
competition ELISA using hMCT-2 derivatives with single-residue Ala substitutions and 
fragment derivatives of hMCT-2. Anti-hMCT-2 mAb was incubated with hMCT-2 or 
each hMCT-2 derivative at 37°C for 2 h. The solution was added to each well of the 
plate with immobilized hMCT-2-EMCS-KLH, and the plate was further incubated at 
37°C for 30 min. The mAb binding to the plate was examined by ELISA as described 
above. 
 
III-3-7. Inhibitory potency of mAb on the activation of neutrophilic cells 
 HL-60 cells (RIKEN Cell Bank, Ibaraki, Japan) were cultured in RPMI-1640 
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medium (Thermo Fisher Scientific, MA, USA) containing 10% fetal bovine serum 
(Thermo Fisher Scientific) in a humidified atmosphere at 37°C and 5% CO2. The cells 
were treated with 500 µM dibutyryl cyclic adenosine monophosphate (Sigma-Aldrich) 
for 72 h to differentiate the cells into neutrophilic/granulocytic cells as described 
elsewhere [5, 24].  
 The inhibitory effects of anti-hMCT-2 mAb on hMCT-2-induced 
β-hexosaminidase (β-HA) release were evaluated in HL-60 cells differentiated into 
neutrophilic/granulocytic cells [41]. Cells were washed 3 times with ice-cold 
HEPES-buffered Hank's solution (HBHS; 10 mM HEPES, 136.9 mM NaCl, 5.4 mM 
KCl, 1.2 mM CaCl2, 0.44 mM KH2PO4, 0.49 mM MgCl2, 0.41 mM MgSO4, 0.34 mM 
Na2HPO4, 5.5 mM glucose, and 4.2 mM NaHCO3, pH 7.4) containing 0.1% bovine 
serum albumin. Then, the cells were resuspended in HBHS at a density of 1.0 × 107 
cells/ml and DNase I (Sigma-Aldrich) and cytochalasin B (Sigma-Aldrich) were each 
added at a final concentration of 5 µg/ml. The cell suspension (5.0 × 105 cells/50 
µl/tube) was pre-incubated at 37°C for 10 min. Then, the cells were stimulated with 50 
µl of peptide solution that had been pre-incubated with or without various 
concentrations of anti-hMCT-2 mAb at 37°C for 2 h. The stimulation was performed at 
37°C for 10 min. These cells were also stimulated at 37°C for 10 min with 50 µl of 
hMCT-2 solution that had been pre-incubated with control mAb (LEAF purified mouse 
IgG1, κ isotype control; BioLegend, CA, USA) at 37°C for 2 h. The stimulation was 
terminated by adding 200 µl of ice-cold reaction quenching buffer (25 mM Tris, 123 
mM NaCl, and 2.7 mM KCl, pH 7.4) to each cell suspension. These tubes were 
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centrifuged at 4°C and 2,300 × g for 1 min, and each cell-free supernatant was 
transferred into a new tube. 
 β-HA activity in the cell-free supernatant was evaluated as described 
previously [5, 41]. Briefly, 90 µl of the cell-free supernatant was transferred to each 
well of a 96-well microtiter plate, and 60 µl of a substrate solution (10 mM 
4-nitrophenyl N-acetyl-β-D-glucosaminide [Sigma-Aldrich] in 40 mM citrate and 70 
mM NaHPO4, pH 4.5) was added for initiation of the enzyme reaction. After incubation 
of the plate at 37°C for 60 min, 100 µl of 400 mM glycine (pH 10.7) was added to stop 
the enzyme reaction. The absorbance at 415 nm and 490 nm (for reference) was 
measured by microtiter plate reader (Viento XS, BioTek Instruments). The β-HA 
release induced by each peptide in the presence of various concentrations of 
anti-hMCT-2 mAb or control mAb was estimated as a percentage of the stimulation of 
each peptide without mAbs. 
 
III-3-8. Statistical analysis 
 The data in the present study are expressed as means ± standard error (SE) in 
experiments containing multiple data points. Statistical comparisons between two 
groups were performed using Student's t-test, and P < 0.05 was considered significant. 
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III-4. Results 
III-4-1. Generation of anti-hMCT-2 mAbs 
 It is important to obtain peptide-specific antibodies against hMCT-2 that 
recognize the cleavage site of hMCT-2 that is presumably generated upon enzymatic 
hydrolysis of its parent protein, cytochrome b, for investigation of its physiological 
production and distribution. Moreover, it is crucial to acquire neutralizing antibodies 
against hMCT-2 for elucidation of its physiological and pathophysiological roles 
because hMCT-2 is a bioactive peptide hidden in its parent protein. To prepare those 
mAbs, hybridoma cells were generated by cell fusion, utilizing spleen cells of mice 
immunized with hMCT-2-EMCS-thyroglobulin, and cloned by limiting dilution. I 
obtained several clones producing mAbs that bound to hMCT-2. I then screened 
features of these mAbs regarding their recognition of the cleavage site and the 
neutralizing potency against the biological functions of hMCT-2. As a result, I acquired 
one clone producing mAb (NhM2A1) that recognized the cleavage site and another 
clone that produced the neutralizing mAb (NhM2A5). I found that the binding of 
NhM2A1 to the plate coated with hMCT-2-EMCS-KLH was inhibited by free hMCT-2, 
but not an hMCT-2 derivative that was elongated by one amino acid at its C-terminus 
(data not shown), suggesting that NhM2A1 recognized the C-terminal cleavage site on 
hMCT-2. I also screened inhibitory potencies of anti-hMCT-2 mAbs in cell culture 
medium on hMCT-2-induced β-HA release in HL-60 cells differentiated into 
neutrophilic/granulocytic cells. NhM2A5 produced from one of the clones prevented 
hMCT-2-induced β-HA release (data not shown). NhM2A1 and NhM2A5 were then 
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purified from the culture medium of those hybridoma clones, and I confirmed that both 
isotypes were IgG1 κ by Isostrip. 
 
III-4-2. Characterization of anti-hMCT-2 mAb recognizing a cleavage site on 
hMCT-2 
 Binding of NhM2A1 (3 nM) to the plate with immobilized 
hMCT-2-EMCS-KLH was significantly prevented by free hMCT-2 (10 µM) (Fig. 
III-1-A). In contrast, other neutrophil-activating peptides, porcine MCT-1 (pMCT-1), 
NADH dehydrogenase subunit 6 (1-6) (ND-6), and formyl-Met-Leu-Phe (fMLF) at 10 
µM did not inhibit the mAb binding (Table III-1, Fig. III-1-A). Cross-binding of 
NhM2A1 to MCT-2 homologs was also examined by competition ELISA. NhM2A1 
binding to the plate was prevented by hMCT-2 in concentration-dependent manner (Fig. 
III-1-B). Porcine and mouse MCT-2 homologs (Table III-1) also dose-dependently 
inhibited the binding, but inhibitory effects were lower than that of hMCT-2 (Fig. 
III-1-B). These results suggest that NhM2A1 binds to hMCT-2 and also can recognize 
porcine MCT-2 and mouse MCT-2. The Kd value of NhM2A1 on the binding to 
hMCT-2 estimated by Scatchard analysis on competition ELISA was 8.2 ± 1.7 nM. 
 Epitope mapping of NhM2A1 was performed by competition ELISA using 
fragment derivatives of hMCT-2. The hMCT-2 (9–15) peptide dose-dependently 
prevented NhM2A1 binding (10 nM) to the plate with immobilized 
hMCT-2-EMCS-KLH, but hMCT-2 (1–7) and hMCT-2 (5–11) did not (Fig. III-2-A). 
These results indicate that the epitope is located in the C-terminal region of hMCT-2. 
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hMCT-2 (10–15), hMCT-2 (11–15), and hMCT-2 (12–15), which are truncated 
derivatives of hMCT-2 (9–15), were then examined for the elucidation of its epitope. 
The hMCT-2 (9–15) and hMCT-2 (10–15) peptides inhibited NhM2A1 binding to the 
plate with similar potencies. On the other hand, the inhibitory effects of hMCT-2 (11–
15) and hMCT-2 (12–15) were dramatically decreased in comparison with that of 
hMCT-2 (10–15). These results demonstrate that an NhM2A1-binding epitope is 
located within hMCT-2 (10–15).  
 Since NhM2A1 bound to hMCT-2 (10–15), it was also investigated whether 
NhM2A1 recognized a cleavage site in hMCT-2 that is generated upon its hydrolysis 
from cytochrome b (Fig. III-2-B). NhM2A1 binding (10 nM) to the plate was almost 
completely prevented by 3 µM hMCT-2 (1–15). In contrast, 3 µM hMCT-2 (1–16), 
hMCT-2 (1–17), and hMCT-2 (1–20), which are hMCT-2 derivatives that are 
C-terminally elongated with the same amino acid residues that cytochrome b has, did 
not inhibit the binding of NhM2A1 to the plate (Fig. III-2-B). These results indicate that 
NhM2A1 recognizes this C-terminal cleavage site on hMCT-2. 
 
III-4-3. Characterization of neutralizing mAb against hMCT-2 
 Binding of NhM2A5 (10 nM) to the plate with immobilized 
hMCT-2-EMCS-KLH was significantly inhibited by free hMCT-2 (10 µM), but not by 
other neutrophil-activating peptides, pMCT-1, ND-6, and fMLF (Fig. III-3-A). 
Cross-binding of NhM2A5 to MCT-2 homologs was also investigated by competition 
ELISA, and it was shown that porcine MCT-2, mouse MCT-2, and control peptide 
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(pMCT-1) did not inhibit the mAb binding (Fig. III-3-B). These results demonstrate that 
NhM2A5 is a specific mAb against hMCT-2. The Kd value of NhM2A5 on the binding 
to hMCT-2 calculated by Scatchard analysis on competition ELISA was 3.1 ± 3.5 nM. 
 Epitopes recognized by NhM2A5 were investigated by competition ELISA 
using hMCT-2 derivatives with single-residue Ala substitutions. Inhibitory activities of 
the derivatives with Ala at position 5, 6, 7, 9, 10, 11, or 12 were significantly decreased 
(Fig. III-4-A), whereas the substitutions at the other positions did not affect the 
inhibitory potency. These results indicate that the side chains at positions 5, 6, 7, 9, 10, 
11 and 12 of hMCT-2 are involved in NhM2A5 binding to hMCT-2. 
 Moreover, an epitope involved in the interaction between NhM2A1 and 
hMCT-2 was confirmed by competition ELISA using hMCT-2 (5–12). hMCT-2 (5–12) 
as well as hMCT-2 (1–15) dose-dependently prevented NhM2A5 binding (10 nM) to 
the plate coated with hMCT-2-EMCS-KLH with the same potency (Fig. III-4-B). These 
results demonstrate that the required structure of hMCT-2 for NhM2A1 binding is 
located in the region from positions 5 to 12 of hMCT-2 and the side chains of amino 
acids at positions 5, 6, 7, 9, 10, 11, and 12 are involved. 
 
III-4-4. Inhibitory potency 
 Because NhM2A5 in the culture medium of a hybridoma clone qualitatively 
prevented the bioactivity of hMCT-2 as described above, I investigated whether the 
mAb inhibited hMCT-2-induced β-HA release from HL-60 cells differentiated into 
neutrophilic/granulocytic cells. As shown in Fig. III-5, β-HA release induced by 
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hMCT-2 (20 nM) was reduced by NhM2A5 in a concentration-dependent manner, 
whereas it was unaffected by control mAb. NhM2A5 did not influence β-HA release 
promoted by pMCT-1 (200 nM), ND-6 (2 nM), or fMLF (2 nM), even at 300 nM. These 
results demonstrate that NhM2A5 specifically inhibits β-HA release induced by 
hMCT-2, indicating that NhM2A5 is a specific neutralizing mAb against the biological 
functions of hMCT-2. 
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III-5. Discussion 
 In the present study, I succeeded in obtaining a peptide-specific anti-hMCT-2 
mAb (NhM2A1), which recognizes a cleavage site of hMCT-2 that is generated upon 
enzymatic hydrolysis of its parent protein, cytochrome b. NhM2A1 was also able to 
bind not only to hMCT-2 but also to porcine and mouse MCT-2, although the binding 
affinities of the porcine and mouse homologs were lower than that of hMCT-2 (Fig. III- 
1-B). However, the affinities of NhM2A1 for the porcine and mouse MCT-2 homologs 
were considered sufficient for their detection, because the Kd value of NhM2A1 against 
hMCT-2 was 8.2 ± 1.7 nM and the inhibitory effects of porcine and mouse MCT-2 on 
NhM2A1 binding to the plate with immobilized hMCT-2-EMCS-KLH were from 
one-third to one-tenth that of hMCT-2 (Fig. III-1-B). These findings demonstrate that 
NhM2A1 can detect hMCT-2 and its mammalian homologs without recognizing its 
parent protein. NhM2A1 is thus expected to be useful for immunostaining of MCT-2; 
that is, NhM2A1 enables examination of the production and distribution of MCT-2 
without detecting its parent protein, not only at the cellular level but also in various 
tissues.  
 Here, I also succeeded in obtaining a specific neutralizing mAb (NhM2A5) 
against the functions of hMCT-2 but not those of other neutrophil-activating peptides 
(Fig. III-5). The epitope of NhM2A5 was found to be in positions 5 to 12 of hMCT-2, 
indicating that the mAb bound to the central region of hMCT-2 (Fig. III-4). Prior 
investigation of the structure-activity relationships of hMCT-2 in its activation of 
neutrophilic cells revealed that hMCT-2 (1–5) was the minimum structure needed to 
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induce β-HA release [42]. The study also showed that the decapeptide sequence from 
positions 6 to 15 of hMCT-2 contribute to the binding affinity between hMCT-2 and its 
receptor, FPR2. Taken together, these findings suggest that NhM2A5 inhibits the 
bioactivities of hMCT-2 by binding to not only the minimum structure containing the 
activation site for FPR2 but also the affinity-involving region of hMCT-2. I successfully 
acquired NhM2A1 that binds to the cleavage site of hMCT-2 and NhM2A5 that 
neutralizes the bioactivity of hMCT-2; thus, it has become possible to investigate the 
physiological functions, production, and distribution of hMCT-2. Recently, 
mitochondrial damage-associated molecular patterns (mtDAMPs) have been focused on 
as inflammation-inducing factors [34–36, 43, 44]. mtDAMPs are proposed to be 
composed of formyl peptides and mtDNA and induce sterile inflammation associated 
with neutrophil migration and activation. However, it has recently been demonstrated 
that highly purified mtDNA does not promote neutrophil activation [39, 40]. On the 
other hand, it has been shown that not only MCT-1 but also MCT-2 and other 
N-formylated peptides derived from mitochondrial proteins encoded in mitochondrial 
DNA (mtDNA) promote activation of neutrophilic cells [5, 6, 45–47]. However, the 
molecules responsible for inducing innate immunological responses including 
neutrophil functions have not been identified in vivo. Recently, using the NhM2A1 
mAb I found hMCT-2 present in mtDAMPs (manuscript in preparation), and are now 
investigating the contribution of hMCT-2 to mtDAMP-induced innate immunity by 
utilizing the inhibitory effects of NhM2A5. These approaches will contribute to 
elucidating the bioactive factors in mtDAMPs. 
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 In conclusion, I sought to establish strategies that enable investigation of the 
physiological roles of hMCT-2 by generating mAbs that recognize its cleavage site and 
that neutralize its physiological functions. The approaches utilizing these mAbs are 
expected to open a new era for the investigation of physiological significance of not 
only MCTs but also cryptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51 
Table III-1. Amino acid sequences of MCTs and other neutrophil-activating peptides                
MCT-1 (Porcine): H-Leu-Ser-Phe-Leu-Ile-Pro-Ala-Gly-Trp-Val-Leu-Ser- 
                 His-Leu-Asp-His-Tyr-Lys-Arg-Ser-Ser-Ala-Ala-OH 
 
MCT-2 (Porcine): formyl-Met-Thr-Asn-Ile-Arg-Lys-Ser-His-Pro-Leu- 
                 Met-Lys-Ile-Ile-Asn-OH 
 
MCT-2 (Human): formyl-Met-Thr-Pro-Met-Arg-Lys-Ile-Asn-Pro-Leu- 
                 Met-Lys-Leu-Ile-Asn-OH 
 
MCT-2 (Mouse):  formyl-Met-Thr-Asn-Met-Arg-Lys-Thr-His-Pro-Leu- 
                 Phe-Lys-Ile-Ile-Asn-OH 
 
ND-6 (1-6):      formyl-Met-Met-Tyr-Ala-Leu-Phe-OH   
 
fMLF:           formyl-Met-Leu-Phe-OH 
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Fig. III-1. Binding specificity of NhM2A1. (A) NhM2A1 binding (3 nM) to a 96-well 
plate with immobilized hMCT-2-EMCS-KLH was investigated by competition ELISA 
using hMCT-2, pMCT-1, ND-6, and fMLF as competitive peptides (10 µM). (B) 
NhM2A1 binding (3 nM) to the plate was examined by competition ELISA using 
human MCT-2, porcine MCT-2, mouse MCT-2, and porcine MCT-1 (control peptide) 
as competitive peptides (10 µM). ***P < 0.001 compared with vehicle. Data are 
expressed as means ± SE of 3 independent experiments. 
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Fig. III-2. Mapping of the NhM2A1 epitope. (A) NhM2A1 epitope was investigated by 
competition ELISA using hMCT-2 and its derivatives on binding of NhM2A1 (10 nM) 
to a 96-well plate with immobilized hMCT-2-EMCS-KLH. (B) Recognition by 
NhM2A1 of the C-terminal cleavage site of hMCT-2 was examined by competition 
ELISA using hMCT-2 derivatives that were elongated with amino acid residues based 
on the sequence of the parent polypeptide, cytochrome b, at its C-terminus. ***P < 
0.001 compared with control peptide (porcine MCT-1). Data are expressed as means ± 
SE of 3 separate experiments. n.s., not significant. 
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Fig. III-3. Binding specificity of NhM2A5. (A) NhM2A5 binding (10 nM) to a 96-well 
plate with immobilized hMCT-2-EMCS-KLH was examined by competition ELISA 
utilizing hMCT-2, pMCT-1, ND-6, and fMLF as competitive peptides (10 µM). (B) 
NhM2A5 binding (10 nM) to the plate was investigated by competition ELISA using 
human MCT-2, porcine MCT-2, mouse MCT-2, and porcine MCT-1 (control peptide) 
as competitive peptides (10 µM). ***P < 0.001 compared with vehicle. Data are 
expressed as means ± SE of 3 independent experiments. 
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Fig. III-4. Mapping of the NhM2A5 epitope. (A) Alanine scanning of hMCT-2 by 
competition ELISA to find the important amino acid residues for binding NhM2A5. 
Inhibitory activity of hMCT-2 derivatives with single-residue Ala substitutions (1 µM) 
was expressed as the ratio to that of hMCT-2 on NhM2A5 binding (10 nM) to a 96-well 
plate with immobilized hMCT-2-EMCS-KLH. (B) Confirmation of minimum epitope 
region on hMCT-2 by competition ELISA using hMCT-2, hMCT-2 (5–12), and control 
peptide (porcine MCT-1). *P < 0.05, **P < 0.01, ***P < 0.001 compared with 
inhibitory activity of hMCT-2. Each value is the mean ± SE of 3 separate experiments. 
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Fig. III-5. Inhibitory effect of NhM2A5 on hMCT-2-induced β-HA release in HL-60 
cells differentiated into neutrophilic/granulocytic cells.  β-HA release from the 
neutrophilic differentiated HL-60 cells stimulated by 50% of effective concentration of 
each peptide without mAbs was defined as positive control (100%). The β-HA release 
in the presence of various concentrations of NhM2A5 or isotype/subclass-matched 
control mAb (ctrl mAb) is expressed as a percentage. Experimental data are expressed 
as means ± SE of 4 separate experiments. 
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Chapter IV 
General conclusions 
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 MCT-1, MCT-2 and MCT-CYC have been identified from healthy porcine 
hearts as endogenous neutrophil-activating peptides and are the peptide fragments 
derived from mitochondrial cytochrome c oxidase subunit VIII, cytochrome b, and 
cytochrome c, respectively. These MCTs efficiently induce neutrophil migration and 
phagocytosis at nano-molar concentrations in vitro, but physiological production, 
localization and roles of MCTs remain unknown. There are two difficulties to 
investigate physiological functions of MCTs that hidden in mitochondrial proteins. One 
is that antibodies that bind to MCT sequences can not distinguish between MCTs and 
their parent proteins. Another reason is that silencing of gene that encoded MCTs 
inevitably affects the functions and expression levels of their parent proteins. In the 
present study, I tried to establish an alternative strategy for investigation of 
physiological and pathophysiological significance of MCTs. 
 Here, I attempted to generate monoclonal antibodies that bind to MCTs but 
not their parent proteins, and that specifically neutralize their bioactivities. Practically, I 
succeeded to obtain specific mAb, NM1B1 that bound to the region of positions 9 to 22 
of MCT-1, and this mAb was shown to specifically prevent MCT-1-induced migration 
and phagocytosis of HL-60 cells differentiated into neutrophilic/granulocytic cells 
(Chapter II). I also acquired two anti-hMCT-2 mAbs with different features. Namely, 
NhM2A1 mAb bound to a cleavage site on hMCT-2 that is created by enzymatic 
hydrolysis of cytochrome b. This characteristic allows analysis of the production and 
localization of hMCT-2 because the mAb specifically binds to hMCT-2 but not to its 
parent protein, cytochrome b. Moreover, another mAb, NhM2A5 that bound to the 
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region of positions 5 to 12 of hMCT-2, was demonstrated to inhibit bioactivities of 
hMCT-2 specifically. This neutralizing mAb allows for investigation of its 
physiological roles without influencing the functions of its parent protein (Chapter III).  
 As described above, functional analysis of not only such MCTs but also 
various cryptides that hidden in protein structures had been presently very difficult. 
Generating specific mAbs against MCTs themselves and specific neutralizing mAbs 
against functions of MCTs contributes to investigation of their production, localization 
and functions in not only cellular levels but also in diseases including ischemia 
reperfusion injury, fulminant hepatic failure. Actually, the presence of MCT-2 in 
mtDAMPs has been shown by the immunoblot using NhM2A1 mAb, which specifically 
binds to MCT-2 very recently. Moreover, it was observed that intravenous injection of 
anti-MCT-1 neutralizing mAb, NM1B1, inhibited the accumulation of neutrophils into 
necrotic area of liver induced by a hepatic toxin, acetaminophen. Thus, this study will 
contribute to overcome the difficulties on elucidation of physiological significances of 
cryptides including MCTs. 
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